All In Biotech

Drug Trial Radar · NCT02907060

Mechanical cervicAl ripeninG for Women With PrOlongedPregnancies

Propess® Versus Double Balloon for Cervical Ripening of Prolonged Pregnancies: a Randomised Controlled Trial

Last checked: Nov 20, 2026Latest source record: Dec 22, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 1,224 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,224

Actual

Start

Jan 27, 2017

Primary completion

Dec 12, 2018

Study completion Dec 12, 2018

Sponsor

Lead sponsor
University Hospital, ToursAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Sep 20, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A pregnancy is considered ''prolonged'' from 41 weeks of gestation. Prolonged Pregnancies (PP) are associated with increased maternal morbidity: emergency caesarean, 3rd and 4th degree perineal lesions and postpartum haemorrhage. Foetuses are at increased risk of oligohydramnios, meconium-staining and Fetal Heart Rate (FHR) anomalies. Around 15% of all pregnancies are prolonged. A Cochrane review on induction of labour showed that a policy of labour induction at or beyond 41 weeks was associated with significantly fewer perinatal deaths. Thus the French College of Obstetricians and Gynaecologists stated, "induction of labour can be proposed to patients between 41+0 and 41+6 weeks of gestation". In cases where labour is induced and cervix is unfavourable, cervical ripening is advised. Methods of cervical ripening include pharmacological (prostaglandins) and mechanical (Foley catheter or trans-cervical double balloon) methods. Those two methods were compared in the PROBAAT trial among women with term pregnancies (beyond 37+0). The rates of caesarean section with these two strategies were identical, however uterine hyper stimulation with FHR anomalies occurred less when cervical ripening was mechanical. Considering pharmacological cervical ripening is associated with more uterine hyper stimulation and more FHR anomalies, it may not be the most appropriate in cases of fragile foetuses that include cases of prolonged pregnancies. Considering prolonged pregnancies are associated with a risk of FHR anomalies and that cervical ripening with a pharmacological method is another factor which increases this risk: women with prolonged pregnancies could benefit from a more "gentle" cervical ripening. At present, no particular method is recommended in cases of cervical ripening and prolonged pregnancies. We hypothesise that, in cases of prolonged pregnancies, mechanical cervical ripening, with less uterine hyperstimulation and fewer FHR anomalies, could be more appropriate and could reduce the rate of caesarean section for suspicion of fetal distress.

Conditions

  • Prolonged Pregnancy

Interventions

  • Mechanical cervical ripeningDevice

    The mechanical cervical ripening is a double transcervical balloon. The device used in the study is the Cook® Cervical Ripening Balloon with CE marked (commercialized by the Cook® laboratory, ref JCRBS-184000). It is a silicone double balloon catheter. Maximum balloon inflation is 80 mL/balloon. It will be used in accordance with user manual

  • Pharmacological cervical ripeningDrug

    The comparative pharmacological procedure is a vaginal slow releasing system of dinoprostone. The form used in the study is Propess (Ferring pharmaceuticals) containing 10mg of dinoprostone (prostaglandin E2). It will be used in accordance with Summary of Product Characteristics

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Caesarean section rate for non-reassuring fetal status.Time frame: Up to 2 days after cervical ripening

Locations

14 sites in 1 country. Site status is shown where the registry gives one.

  • Chu Brest

    Brest, France

  • CHU CAEN

    Caen, France

  • Ch Pontoise

    Cergy-Pontoise, France

  • Ch Chartres

    Chartres, France

  • Chu Clermont-Ferrand

    Clermont-Ferrand, France

  • Ch Departemental Vendee

    La Roche-sur-Yon, France

  • Hopital Saint Joseph

    Marseille, France

  • Chu Nantes

    Nantes, France

  • Chi Poissy

    Poissy, France

  • Chu Reims

    Reims, France

  • Chu Rennes

    Rennes, France

  • Chu Saint Etienne

    Saint-Priest-en-Jarez, France

  • Chu Toulouse

    Toulouse, France

  • Chru Tours

    Tours, France

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.